Accuray (ARAY) to Release Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Accuray has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The firm had revenue of $107.24 million during the quarter, compared to the consensus estimate of $107.11 million. Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. During the same quarter last year, the company posted ($0.02) EPS. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

ARAY opened at $2.19 on Monday. The stock has a fifty day simple moving average of $2.49 and a two-hundred day simple moving average of $2.64. The company has a current ratio of 1.58, a quick ratio of 0.84 and a debt-to-equity ratio of 3.53. The company has a market cap of $217.18 million, a price-to-earnings ratio of -14.60 and a beta of 1.44. Accuray has a 12-month low of $2.10 and a 12-month high of $4.30.

Analysts Set New Price Targets

ARAY has been the subject of a number of research reports. TheStreet downgraded Accuray from a “c-” rating to a “d+” rating in a report on Wednesday, February 14th. Roth Mkm initiated coverage on Accuray in a report on Tuesday, February 13th. They set a “buy” rating and a $9.00 price target for the company. Finally, Roth Capital restated a “buy” rating on shares of Accuray in a report on Tuesday, February 13th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Accuray currently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.